高剂量阿糖胞苷 (HDAC) 常规上在第 1、3、5 天给予 (HDAC-135) 作为急性髓性白血病 (AML) 缓解期治疗。很少有数据可以用来比较其他 HDAC 方案，如 HDAC-123 (连续给予 3 天)。我们回顾性比较了连续入组的成年 AML 患者中 HDAC-135 和 HDAC-123 的耐受性和疗效。共包括 73 名患者，其中 33% 的患者年龄 ≥60 岁。HDAC-123 与更快的造血恢复、较少的细菌血症和较短的住院时间有关。在 HDAC-123 组接受治疗的 ≥60 岁和 <60 岁患者之间，在安全性和造血恢复方面没有差异，只有后者在第 1 个疗程后中性粒细胞计数恢复的中位时间较短。三名 (8%) 接受 HDAC-123 治疗的患者，均为 <60 岁年龄组，因暂时性的阿糖胞苷相关副作用需要把方案改为 HDAC-135。AML 患者对 HDAC-123 合并治疗耐受良好，包括 ≥60 岁年龄组，且与资源利用有明显减少相关。

High-dose cytarabine (HDAC) is conventionally delivered on days 1, 3 and 5 (HDAC-135) as acute myeloid leukemia (AML) post-remission therapy. Limited data is available on alternative HDAC schedules such as HDAC-123 (given consecutively for 3 days). We retrospectively compared the tolerability and efficacy of HDAC-135 and HDAC-123 delivered in sequential cohorts of adult AML patients. Seventy-three patients were included with 33% aged ≥60 years. HDAC-123 was associated with faster hematological recovery, reduced bacteremia and shorter hospitalization. No differences in safety profile or hematological recovery were seen between patients ≥60 years and <60 years receiving HDAC-123 except a shorter median time to neutrophil count recovery after cycle 1 in the latter group. Three patients (8%) receiving HDAC-123, all aged <60 years, required a change in schedule to HDAC-135 due to transient cytarabine-related side effects. HDAC-123 consolidation was well-tolerated by AML patients, including those ≥60 years, and associated with tangible reductions in resource utilization.